|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xie Y: Hepatitis B virus-associated
hepatocellular carcinoma. Adv Exp Med Biol. 1018:11–21. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang Y, Han QJ and Zhang J:
Hepatocellular carcinoma: Mechanisms of progression and
immunotherapy. World J Gastroenterol. 25:3151–3167. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Piñero F, Dirchwolf M and Pessôa MG:
Biomarkers in hepatocellular carcinoma: Diagnosis, prognosis and
treatment response assessment. Cells. 9:13702020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dimri M and Satyanarayana A: Molecular
signaling pathways and therapeutic targets in hepatocellular
carcinoma. Cancers (Basel). 12:4912020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Akula SM, Abrams SL, Steelman LS, Emma MR,
Augello G, Cusimano A, Azzolina A, Montalto G, Cervello M and
McCubrey JA: RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53
pathways and regulatory miRs as therapeutic targets in
hepatocellular carcinoma. Expert Opin Ther Targets. 23:915–929.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fujiwara N, Friedman SL, Goossens N and
Hoshida Y: Risk factors and prevention of hepatocellular carcinoma
in the era of precision medicine. J Hepatol. 68:526–549. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xing R, Gao J, Cui Q and Wang Q:
Strategies to improve the antitumor effect of immunotherapy for
hepatocellular carcinoma. Front Immunol. 12:7832362021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen Y, Li L, Lan J, Cui Y, Rao X, Zhao J,
Xing T, Ju G, Song G, Lou J and Liang J: CRISPR screens uncover
protective effect of PSTK as a regulator of chemotherapy-induced
ferroptosis in hepatocellular carcinoma. Mol Cancer. 21:112022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hoogeveen AT, Willemsen R and Oostra BA:
Fragile X syndrome, the Fragile X related proteins, and animal
models. Micros Res Tech. 57:148–155. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Majumder M, Johnson RH and Palanisamy V:
Fragile X-related protein family: A double-edged sword in
neurodevelopmental disorders and cancer. Crit Rev Biochem Mol Biol.
55:409–424. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jin X, Zhai B, Fang T, Guo X and Xu L:
FXR1 is elevated in colorectal cancer and acts as an oncogene.
Tumour Biol. 37:2683–2690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Majumder M and Palanisamy V: RNA binding
protein FXR1-miR301a-3p axis contributes to p21WAF1 degradation in
oral cancer. PLoS Genet. 16:e10085802020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao S, Zheng J, Liu X, Liu Y, Ruan X, Ma
J, Liu L, Wang D, Yang C, Cai H, et al: FXR1 promotes the malignant
biological behavior of glioma cells via stabilizing MIR17HG. J Exp
Clin Cancer Res. 38:372019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao M, Mishra L and Deng CX: The role of
TGF-β/SMAD4 signaling in cancer. Int J Biol Sci. 14:111–123. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Colak S and Ten Dijke P: Targeting TGF-β
signaling in cancer. Trends Cancer. 3:56–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hao Y, Baker D and Ten Dijke P:
TGF-β-mediated epithelial-mesenchymal transition and cancer
metastasis. Int J Mol Sci. 20:27672019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu HH, Chen DQ, Wang YN, Feng YL, Cao G,
Vaziri ND and Zhao YY: New insights into TGF-β/Smad signaling in
tissue fibrosis. Chem Biol Interact. 292:76–83. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aashaq S, Batool A, Mir SA, Beigh MA,
Andrabi KI and Shah ZA: TGF-β signaling: A recap of
SMAD-independent and SMAD-dependent pathways. J Cell Physiol.
237:59–85. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pallasch FB and Schumacher U: Angiotensin
Inhibition, TGF-β and EMT in Cancer. Cancers (Basel). 12:27852020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Suarez-Carmona M, Lesage J, Cataldo D and
Gilles C: EMT and inflammation: Inseparable actors of cancer
progression. Mol Oncol. 11:805–823. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Babaei G, Aziz SG and Jaghi NZZ: EMT,
cancer stem cells and autophagy; The three main axes of metastasis.
Biomed Pharmacother. 133:1109092021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Syed V: TGF-β signaling in cancer. J Cell
Biochem. 117:1279–1287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang K, Fang T, Shao Y and Wu Y:
TGF-β-MTA1-SMAD7-SMAD3-SOX4-EZH2 signaling axis promotes viability,
migration, invasion and EMT of hepatocellular carcinoma cells.
Cancer Manag Res. 13:7087–7099. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cao H, Gao R, Yu C, Chen L and Feng Y: The
RNA-binding protein FXR1 modulates prostate cancer progression by
regulating FBXO4. Funct Integr Genomics. 19:487–496. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li K, Du Y, Li L and Wei DQ:
Bioinformatics approaches for anti-cancer drug discovery. Curr Drug
Targets. 21:3–17. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Anashkina AA, Leberfarb EY and Orlov YL:
Recent trends in cancer genomics and bioinformatics tools
development. Int J Mol Sci. 22:121462021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tsimberidou AM: Targeted therapy in
cancer. Cancer Chemother Pharmacol. 76:1113–1132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoshida K, Murata M, Yamaguchi T,
Matsuzaki K and Okazaki K: Reversible human TGF-β signal shifting
between tumor suppression and fibro-carcinogenesis: Implications of
smad phospho-isoforms for hepatic epithelial-mesenchymal
transitions. J Clin Med. 5:72016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fransvea E, Angelotti U, Antonaci S and
Giannelli G: Blocking transforming growth factor-beta up-regulates
E-cadherin and reduces migration and invasion of hepatocellular
carcinoma cells. Hepatology. 47:1557–1566. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bai X, Yi M, Jiao Y, Chu Q and Wu K:
Blocking TGF-β signaling to enhance the efficacy of immune
checkpoint inhibitor. Onco Targets Ther. 12:9527–9538. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bakir B, Chiarella AM, Pitarresi JR and
Rustgi AK: EMT, MET, plasticity, and tumor metastasis. Trends Cell
Biol. 30:764–776. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu W and Kang Y: Epithelial-mesenchymal
plasticity in cancer progression and metastasis. Dev Cell.
49:361–374. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yuan GJ, Li QW, Shan SL, Wang WM, Jiang S
and Xu XM: Hyperthermia inhibits hypoxia-induced
epithelial-mesenchymal transition in HepG2 hepatocellular carcinoma
cells. World J Gastroenterol. 18:4781–4786. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kimura-Tsuchiya R, Ishikawa T, Kokura S,
Mizushima K, Adachi S, Okajima M, Matsuyama T, Okayama T, Sakamoto
N, Katada K, et al: The inhibitory effect of heat treatment against
epithelial-mesenchymal transition (EMT) in human pancreatic
adenocarcinoma cell lines. J Clin Biochem Nutr. 55:56–61. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang J, Xu Z, Wang Z, Du G and Lun L:
TGF-beta signaling in cancer radiotherapy. Cytokine.
148:1557092021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang M, Zhang YY, Chen Y, Wang J, Wang Q
and Lu H: TGF-β signaling and resistance to cancer therapy. Front
Cell Dev Biol. 9:7867282021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li H, He G, Yao H, Song L, Zeng L, Peng X,
Rosol TJ and Deng X: TGF-β induces degradation of PTHrP through
ubiquitin-proteasome system in hepatocellular carcinoma. J Cancer.
6:511–518. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Suwa K, Yamaguchi T, Yoshida K, Murata M,
Ichimura M, Tsuneyama K, Seki T and Okazaki K: Smad
phospho-isoforms for hepatocellular carcinoma risk assessment in
patients with nonalcoholic steatohepatitis. Cancers (Basel).
12:2862020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yoshida K, Matsuzaki K, Murata M,
Yamaguchi T, Suwa K and Okazaki K: Clinico-pathological importance
of TGF-β/phospho-smad signaling during human hepatic
fibrocarcinogenesis. Cancers (Basel). 10:1832018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kaminska B, Wesolowska A and Danilkiewicz
M: TGF beta signalling and its role in tumour pathogenesis. Acta
Biochim Pol. 52:329–337. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Burkhart RA, Ronnekleiv-Kelly SM and
Pawlik TM: Personalized therapy in hepatocellular carcinoma:
Molecular markers of prognosis and therapeutic response. Surg
Oncol. 26:138–145. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Qin LX and Tang ZY: The prognostic
molecular markers in hepatocellular carcinoma. World J
Gastroenterol. 8:385–392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Stefani C, Miricescu D, Stanescu S II,
Nica RI, Greabu M, Totan AR and Jinga M: Growth factors,
PI3K/AKT/mTOR and MAPK signaling pathways in colorectal cancer
pathogenesis: Where are we now? Int J Mol Sci. 22:102602021.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shorning BY, Dass MS, Smalley MJ and
Pearson HB: The PI3K-AKT-mTOR pathway and prostate cancer: At the
crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci.
21:45072020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kumari N, Reabroi S and North BJ:
Unraveling the molecular nexus between GPCRs, ERS, and EMT.
Mediators Inflamm. 2021:66554172021. View Article : Google Scholar : PubMed/NCBI
|
